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RESPONSE TO LETTER
“Reply to Slankamenac
et al’s Comprehensive
Complication Index
Validation Study
(November 2014)”
Reply:
W e greatly appreciate the positive in-terest by Dr O Boney, Dr R.
Moonesinghe, and Professor M. Grocott in
our article published in Annals of Surgery in
November 2014.1 We thank them for high-
lighting the important role and need for a
composite endpoint for surgical complica-
tions such as the comprehensive complica-
tions index (CCI).1,2
Boney et al were interested in the
methodology of the external validation of
the CCI in 3 randomized controlled trials
(RCT),3–5 which were initially conducted for
specific surgical complications as a primary
endpoint and not for a composite endpoint.
From a methodological point of view, it is
not a problem to validate the CCI using RCTs
which had different primary endpoints as long
as all complications were ascertained. To en-
sure that we only relied on RCTs with high
quality data on complications, we visited ev-
ery center and assessed on site each postop-
erative complication in each patient, and then
graded them according to the Clavien–Dindo
classification.6 With these visits, we ensured
the completeness of complications and a har-
monized approach to grade them across trials
and to calculate the CCI.
Boney et al also raised the question if
a composite endpoint is the best primary end-
point in RCT or not because it may mask im-
portant differences in specific complication
rates. We are convinced that both the com-
posite outcome measure and specific compli-
cations have advantages and disadvantages.
This is exemplified by the trials comparing
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different surgical procedures or treatments.
One patient group had a short-term advan-
tage in terms of the primary outcome but that
outcome did not consider the overall patient
experience. Such focus on single endpoints is
neglecting all other complications and likely
to mask harms that contribute to the overall
complications. The CCI as a composite com-
plication score might indeed mask important
differences in specific complication rates at
different time points, but it has the advantage
to reflect the overall burden of the postop-
erative course which is affecting the health
of patients and their quality of life. There-
fore, we recommend reporting both the single
complications and the CCI to inform treat-
ment decisions.2
Another comment by Boney et al dis-
cussed the minimal important difference of
the CCI for determining the sample size for
RCTs and for interpreting trial results. We
greatly appreciate this important comment
and essentially agree that it is difficult to con-
clusively determine the minimal important
difference of the CCI. Because of the non-
linear nature of the CCI, it is unlikely that a
10-point difference applies across the range.
Therefore, sample size calculations also re-
quire clinical judgment. Sometimes a 10-
point difference is adequate whereas in other
situations a smaller or larger difference of the
CCI may be perceived important enough to
change treatment decisions. It is important
though to decide on the minimal important
difference a priori and report it transparently.
Finally, we agree with Boney et al
and also strongly recommend evaluating the
CCI in future trials, which we already rec-
ommended in the discussion of our current
publication in November 2014.1
In conclusion, we need to learn through
further studies about the minimal impor-
tant difference across the range of the CCI.
We are looking forward to results of further
studies using and discussing the CCI as an
overall measure of morbidity after surgical
procedures. We are convinced that so far,
the CCI reflects best the overall burden of
the postoperative course and mainly, repre-
sents the health of patients and their qual-
ity of life after surgery. Additionally, the CCI
may allow in the future better information of
patients, standardized reporting in outcome
research, and increased comparability and
benchmarking of quality of surgery across
centers.
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